1 -term and long-term side-effects that may be
intolerable.
2 east one of which included bexarotene unless
intolerable.
3 rogression was evident or toxic effects were
intolerable.
4 t they can escape if their suffering becomes
intolerable.
5 ]; n = 51) until disease progression, death,
intolerable adverse effects, or withdrawal of consent.
6 , this treatment strategy is associated with
intolerable adverse effects.
7 ess disease recurrence or new breast cancer,
intolerable adverse events, or consent withdrawal occurr
8 nfarction (MI) is frequently hemodynamically
intolerable and associated with multiple electrocardiogr
9 use by promoting the opinion that niacin is
intolerable and contraindicated in diabetes.
10 oes brain ACh receptors, smoking would cause
intolerable and perhaps fatal muscle contractions.
11 5 oral formulation on the daily schedule was
intolerable at a dose and schedule explored.
12 The
intolerable burden of malaria has for too long plagued h
13 patients for whom imatinib is ineffective or
intolerable,
but that could also be combined with the in
14 Side effects were described as
intolerable by 6 (8%) and their beta-blockers were stopp
15 ld provoke an inflammatory response and thus
intolerable conditions for the cells.
16 earlier critical mechanical constraints and
intolerable dyspnea.
17 Intolerable exposure levels were not encountered.
18 less than the release of source programs is
intolerable for results that depend on computation.
19 However, systemic reactions and
intolerable gastrointestinal AEs do occur and are signif
20 ions of mucosal integrity or, more commonly,
intolerable GI symptoms that may necessitate discontinua
21 o of four patients had DLTs (grade 3 nausea;
intolerable grade 2 fatigue).
22 ose-escalation phase (grade 3 acne [n=1] and
intolerable grade 2 mucosal inflammation [n=1]); hence,
23 (diarrhea, nausea, weight loss) that make it
intolerable in some patients.
24 response for the few whose suffering becomes
intolerable in spite of optimal palliative care.
25 These toxicities were
intolerable in two of six patients after receiving three
26 in the HypoPP trial was the occurrence of an
intolerable increase in attack severity or frequency (en
27 eases in mean blood pressure of > or =20% or
intolerable itching.
28 (11%) were removed from the study because of
intolerable joint pain.
29 ited replicative potential but also prevents
intolerable levels of chromosomal instability.
30 ivation of a p53-dependent checkpoint and/or
intolerable levels of genomic instability.
31 mutation rates in an adapting population to
intolerable levels.
32 dynamics during the printing process lead to
intolerable microstructures with large columnar grains a
33 Intolerable mucosal toxicity occurred at higher doses of
34 s refractory to opioid therapy or those with
intolerable opioid-related adverse effects.
35 lable for patients with trigeminal neuralgia
intolerable or resistant to medical therapy.
36 inical symptoms of endometriosis are chronic
intolerable pelvic pain and subfertility or infertility,
37 receptor essential volume (i.e., sterically
intolerable receptor regions).
38 applicability of highly potent but otherwise
intolerable regimens of cancer immunotherapy.
39 Relapse, untreated psychosis,
intolerable side effects and the lack of effective treat
40 ir assigned treatment owing to inefficacy or
intolerable side effects or for other reasons.
41 need to be applied in patients experiencing
intolerable side effects that they attribute to statins.
42 The times to discontinuation because of
intolerable side effects were similar among the groups,
43 s neuroprotective only at doses that produce
intolerable side effects, including memory impairment.
44 scontinuing treatment due to low efficacy or
intolerable side effects, it is important to explore alt
45 roleptics had been ineffective, had produced
intolerable side effects, or both.
46 y abandoned because of a lack of efficacy or
intolerable side effects.
47 iscontinued treatment secondary to 1 or more
intolerable side effects.
48 tional chemotherapies cause many unwanted or
intolerable side effects.
49 doses (50 mg/day and 100 mg/day) resulted in
intolerable side effects.
50 nadequate for certain types of pain or cause
intolerable side effects.
51 for 8 hours unless limited by hypotension or
intolerable side effects.
52 until disease progression or development of
intolerable side-effects.
53 teriorated with treatments, while others had
intolerable side-effects.
54 mg) or placebo until disease progression or
intolerable study drug-related toxicity.
55 ing, but there remain some patients for whom
intolerable suffering persists.
56 Patients who developed AI-associated
intolerable symptoms and discontinued treatment were giv
57 on abnormalities, hypotension, arrhythmia or
intolerable symptoms) was not reached at 3 min of the pe
58 However, for patients with
intolerable symptoms, therapeutic measures are warranted
59 k capacity until they had to stop because of
intolerable symptoms.
60 ever, if the side-effects of anastrozole are
intolerable,
then switching to tamoxifen is a good alter
61 On a scale of 0 (
intolerable)
to 10 (very tolerable) patients rated DPDT
62 ent is required until disease progression or
intolerable toxic effects occur.
63 eatment continued until disease progression,
intolerable toxic effects, or withdrawal of consent.
64 t was continued until disease progression or
intolerable toxic effects.
65 until disease progression or development of
intolerable toxic effects.
66 of chemotherapy until disease progression or
intolerable toxic side-effects occurred.
67 ht combat leukemic growth while avoiding the
intolerable toxicities of NOTCH inhibitors.
68 DS-KS who experienced disease progression or
intolerable toxicities while receiving standard doxorubi
69 y was continued until disease progression or
intolerable toxicities.
70 It is unknown whether patients with
intolerable toxicity from one AI are able to tolerate an
71 orinostat daily until disease progression or
intolerable toxicity in this open-label phase IIb trial
72 fications in the regimen should be done when
intolerable toxicity occurs or if viral load is increase
73 ot complete the planned treatment because of
intolerable toxicity or social problems.
74 cycles, until progressive disease, or until
intolerable toxicity resulted.
75 /kg every 3 weeks until disease progression,
intolerable toxicity, or consent withdrawal.
76 3 weeks continued until disease progression,
intolerable toxicity, or investigator decision.
77 eatment continued until disease progression,
intolerable toxicity, or patient' s decision to disconti
78 0 mg/d or placebo until disease progression,
intolerable toxicity, or the end of 5 years.
79 e of 400 mg/m(2)) until disease progression,
intolerable toxicity, or withdrawal of consent.
80 ks for up to 2 years or disease progression,
intolerable toxicity, withdrawal of consent, or investig
81 every 3 weeks, until disease progression or
intolerable toxicity.
82 Erlotinib was continued until progression or
intolerable toxicity.
83 tment continued until disease progression or
intolerable toxicity.
84 were treated until progression of disease or
intolerable toxicity.
85 gimen continued until disease progression or
intolerable toxicity.
86 described for unmappable or hemodynamically
intolerable VT.
87 An spt16 mutation was found to be
intolerable when combined with a mutation in any member
88 te approaches when imatinib is inadequate or
intolerable,
yet direct comparison in trials is lacking.